Genmab stock price target raised to $40 from $36 at H.C. Wainwright
PositiveFinancial Markets

Genmab's stock price target has been raised from $36 to $40 by H.C. Wainwright, reflecting growing confidence in the company's future performance. This adjustment is significant as it indicates analysts' optimism about Genmab's potential, which could attract more investors and positively impact the stock market.
— Curated by the World Pulse Now AI Editorial System